Idarucizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Idarucizumab
Monoclonal antibody
TypeFab fragment
SourceHumanized (from mouse)
TargetDabigatran
Clinical data
Trade namesPraxbind
SynonymsBI 655075
License data
ATC code
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC2131H3299N555O671S11
Molar mass47.8 kg/mol g·mol−1

Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody designed for the reversal of anticoagulant effects of dabigatran.[1][2]

This drug was developed by Boehringer Ingelheim Pharmaceuticals. A study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation by dabigatran within minutes.[3] It was FDA approved in October 2015.[4] In the United States the wholesale cost is $3500 US.[5]

See also[edit]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Idarucizumab, American Medical Association.
  2. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
  3. ^ Pollack, Charles V.; Reilly, Paul A.; Eikelboom, John; Glund, Stephan; Verhamme, Peter; Bernstein, Richard A.; Dubiel, Robert; Huisman, Menno V.; Hylek, Elaine M. (2015-08-06). "Idarucizumab for Dabigatran Reversal". The New England Journal of Medicine. 373 (6): 511–520. doi:10.1056/NEJMoa1502000. ISSN 1533-4406. PMID 26095746.
  4. ^ "Press Announcements - FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa". www.fda.gov. Retrieved 2015-10-17.
  5. ^ Elia, Joe. "Dabigatran-Reversal Agent Price Set". Retrieved 20 October 2015.